Testicular germ cell tumors (TGCT) are the most common malignant neoplasm in young men. DNA mismatch repair deficiency can lead to microsatellite instability (MSI), an important mechanism of genetic instability. A mutation of the BRAF gene has been implicated in the pathogenesis of several solid tumors and has recently become an important therapeutic target. The role of MSI and BRAF gene mutation in TGCT, particularly in refractory disease, is poorly understood and reported findings are controversial. In this study, we aimed to determine the frequency and clinical impact of MSI status and BRAF mutations in TGCT. DNA was isolated from formalin-fixed paraffin embedded (FFPE) tissue from 150 TGCT cases. The MSI phenotype was evaluated using multiplex PCR for five quasimonomorphic mononucleotide repeat markers. Exon 15 of the BRAF oncogene (V600E) was analyzed by PCR, followed by direct sequencing. Sixteen percent of cases were considered to have refractory disease. In a small subset of cases (17 for MSI and 18 for BRAF), the quantity and quality of DNA recovery were poor and therefore, were unable to be analyzed. The remaining 133 TGCT cases showed a complete absence of MSI. Of the 132 cases successfully evaluated for BRAF mutations, all were V600E wild-type. In conclusion, despite a distinct response of testicular germ cell tumors to therapy, microsatellite instability, and the BRAF V600E mutation were absent in all testicular germ cell tumors tested in this study.
INTRODUCTION
Testicular germ cell tumors (TGCT) are the most frequent malignant neoplasm found in young men and represent 95% of testicular cancers (Bray et al., 2006) . Commonly, TGCTs are classified into two distinct groups, seminomas (SE) and non-seminomas (non-SE). The mainstay treatment for both over the last few decades has been platinum-based chemotherapy and surgery, leading to robust response and cure rates (Einhorn, 2002; Feldman, 2015) . Patients with advanced disease achieve a 5-year-overall survival of more than 70% (Ries et al., 2007) , while those with non-SE have a poorer prognosis and 5-year-overall survival of 50% (IGCCCG, 1997) . Fifteen percent of all patients will develop refractory disease representing a challenge in the clinical management (Mead et al., 2005; Lorch et al., 2010) .
The integrity of the genome depends on the coordinated action of DNA repair genes, also known as 'caretakers' (Kinzler & Vogelstein, 1997) . The failure of one type of such caretakers, a DNA mismatch repair gene, contributes to genome instability by making microsatellite regions more susceptible to mismatch, leading to what is termed microsatellite instability (MSI) (Imai & Yamamoto, 2008; Shah et al., 2010) . The MSI phenotype is a hallmark of hereditary non-polyposis colorectal cancer (HNPCC) syndrome, but is also present in 10-15% of sporadic colorectal cancers (Kinzler & Vogelstein, 1996; Hamelin et al., 2008; Gryfe, 2009) . MSI phenotype has also been described in other cancers including endometrial and gastric (Hamelin et al., 2008) . Recently, colorectal and non-colorectal tumors with identified mismatch-repair defects have been reported as more responsive to a new anti-programmed death 1 immune checkpoint inhibitor drug, highlighting a new role for MSI in immunotherapeutic prediction (Le et al., 2015) .
The BRAF oncogene is an important part of the MAPK (Mitogen Activated Protein Kinase) cellular signaling pathway and related to cell proliferation, differentiation and survival (Kolch, 2000) . BRAF is activated by hotspot mutations, mainly V600E, which has been found in melanomas and other types of cancer (Rajagopalan et al., 2002; Michaloglou et al., 2008) . Recently, the BRAF V600E mutation has emerged as a therapeutic target in melanoma, changing the natural history of the disease (Chapman et al., 2011) .
In TGCT, the roles of MSI and BRAF mutations are poorly characterized and controversial results have been reported (Huddart et al., 1995; Mayer et al., 2002; Velasco et al., 2004 Velasco et al., , 2008 Sommerer et al., 2005; Honecker et al., 2009; MasqueSoler et al., 2011) . Therefore, in the present study, we evaluated the presence and clinical impact of MSI and BRAF mutations in a large series of TGCTs.
MATERIALS AND METHODS

Patients and specimens
Formalin-fixed paraffin-embedded (FFPE) tissues from 150 consecutive cases of testicular germ cell tumors were retrieved from the Biobank of the Departments of Pathology at Barretos Cancer Hospital (Brazil) and Hospital de Braga (Portugal). All patients were diagnosed between 2006 and 2012 and all analyzed samples were collected from primary tumors at diagnosis prior to the use of any systemic treatment. All TGCT cases were independently re-evaluated by a pathologist for diagnosis confirmation.
Germ cell tumor cell lines
The germ cell tumor cell lines NTERA-2, 1411H, 1777N and N2102Ep Clone2/A6 were purchased from the European Collection of Cell Cultures (ECACC). Cell lines were cultured in DMEM containing 2 mM glutamine and 10% FBS (Sigma Aldrich, St. Louis, MO, USA). After achieving 80% confluence, cell lines were trypsinized, washed twice with 1% PBS, and centrifuged. DNA was isolated using the TRIZOL reagent (Life Technologies, Bethesda, MD, USA) and manufacturer's recommendations were followed.
DNA isolation from FFPE tissue
DNA was obtained from FFPE tissue sections representative of tumor pathology as previously described (Martinho et al., 2009a, b; Yamane et al., 2014) , with minor modifications. Briefly, 10 lm thick unstained sections of paraffin blocks were sectioned and one H&E section was used for identification and selection of the tumor area, which was then macrodissected into a microfuge tube using a sterile needle (Neolus, 25G -0.5 mm). The macrodissected tissue was deparaffinized by a serial wash with xylol and ethanol (100-70-50%) and allowed to air-dry. DNA was isolated using the QIAamp â DNA Micro Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. The quality and concentration of DNA were measured using a Nanodrop 2000 Spectrophotometer and stored at À20°C until molecular analysis.
Microsatellite instability analysis
Microsatellite instability evaluation was performed using multiplex PCR for five quasimonomorphic mononucleotide repeat markers (NR-27, NR-21, NR-24, BAT-25, and BAT-26) as previously described (Viana-Pereira et al., 2011; Campanella et al., 2014; Yamane et al., 2014) . Briefly, each antisense primer was end-labeled with a fluorescent dye: FAM (6-carboxyfluorescein) for BAT-26 and NR-21, VIC (2 0 -chloro-7 0 -phenyl-1,4-dichloro-6-carboxyfluorescein) for and NED (2, 7, 4, for NR-24. PCR was performed using the Qiagen Multiplex PCR Kit (Qiagen) with 0.5 lL of DNA at 50 ng/lL. All five markers were co-amplified in a standard multiplex PCR (denaturation at 95°C for 15 min, 40 cycles of denaturation at 95°C for 30 sec, annealing at 55°C for 90 sec and extension at 72°C for 30 sec, followed by a final extension at 72°C for 40 min). PCR products were then submitted to capillary electrophoresis on an ABI 3500xL Genetic Analyzer (Applied Biosystems, Austin, TX, USA) according to the manufacturer's instructions. Results were analyzed using GENEMAPPER v4.1 (Applied Biosystems) software.
In a recent study, our group determined the quasimonomorphic variation range (QMVR) of each marker for the Brazilian population (Campanella et al., 2014) . Accordingly, samples were considered MSI-H when two or more markers were altered and MSI-low (MSI-L) when only one marker was altered, with further validation by MSI analysis of normal tissue or immunohistochemistry of the mismatch repair (MMR) enzymes. Samples were considered microsatellite stable (MSS) when none of the markers were altered.
The HCT-15 colorectal cancer cell line was used as a positive control of MSI-High (MSI-H) in all MSI analyses. DNA from HCT-15 cells was extracted using the TRIZOL reagent (Life Technologies) following the manufacturer's protocol.
In 10% of samples, the MSI analysis was repeated for quality control.
Mutational analysis of BRAF
Hotspot regions (exon 15) of the oncogene BRAF (codon 600) were analyzed by polymerase chain reaction (PCR), followed by direct sequencing, as previously described by our group (Basto et al., 2005; Martinho et al., 2009a,b; Yamane et al., 2014) .
Polymerase chain reactions were performed in a final volume of 15 lL, according the following conditions: 1.5 lL buffer (Qiagen); 2 mM MgCl 2 (Qiagen); 100 mM dNTPs (Invitrogen, Carlsbad, CA, USA); 0.3 mM of both sense and anti-sense primers (Sigma Aldrich), 1 unit of HotStarTaq DNA polymerase (Qiagen) and 1 lL of DNA. The BRAF primers used were: 5 0 -TCA-TAATGCTTGCTCTGATAGGA-3 0 (sense) and 5 0 -GGCCAAAAATT-TAATCAGTGGA-3 0 (antisense) (Basto et al., 2005; Martinho et al., 2009a,b; Yamane et al., 2014) . The PCR was performed with a Veriti thermocycler (Applied Biosystems) and products were evaluated by electrophoresis in 1% agarose gel. All PCR products were purified with EXO-SAP (GE Techonology, Cleveland, OH, USA), and submitted for a sequencing reaction using 1 lL of BigDye (Applied Biosystems), 1.5 lL of sequencing buffer (Applied Biosystems) and 1 lL of primer. Sequencing reactions were followed by post-sequencing purification with EDTA, alcohol and sodium citrate. PCR products were eluted in Hi-Di (formamide) and incubated at 95°C for 5 min and subsequently cooled at À4°C for at least 5 min. Direct sequencing was performed on an ABI 3500 series Genetic Analyzer (Applied Biosystems).
In 10% of samples, the BRAF mutation analysis was repeated for quality control.
Statistical analysis
We assessed measurements of frequency, central tendency, and dispersion for clinical and pathological characteristics. The overall survival was assessed using Kaplan-Meier methods. All diagnostics were performed by orchidectomy before any systemic therapy. Date of diagnosis was the starting point for the survival analysis and events were defined as all-cause mortality. Patients lost to follow-up or alive at the time of this analysis were censored. Survival curves were compared using Logrank tests. The two-sided p-values were considered statistically significant at <0.05. All statistical analyses were performed using SPSS 19.0 software (IBM Corp, Armonk, NY, USA).
RESULTS
One hundred and fifty cases of TGCT were retrieved. After DNA isolation, 17 cases of MSI and 18 cases of BRAF yielded inconclusive results as a result of poor quality and quantity of extracted DNA. The clinicopathological features of all validated cases are summarized in Table 1 .
The mean age of diagnosis was 30 years old and the majority of cases (~68%) had non-SE. The predominant histologies identified were mixed tumor followed by seminoma. All stages of disease were observed, while advanced disease was the most frequent stage identified. Among those who received chemotherapy, around 16% were considered to have refractory disease after treatment with the first-line chemotherapy regimen, BEP (Bleomicine, Etoposide and Cisplatin). A majority of cases were classified as having intermediate or high-risk disease according to IGCCCG. Median follow-up was 36.0 months for cases evaluating MSI and 35.5 months for BRAF evaluated cases. Five-year overall survival was 84.5 and 83.2% for MSI and BRAF evaluated cases, respectively.
Among treatment-refractory patients, the mean age was 29 (min: 20 years and max: 51 years) and 87% of tumors were non-SE. A single case was categorized as stage II, while all other cases were stage III. Eighty-five percent of valid cases presented with two or more sites of metastasis and 95% were classified as high or intermediate risk according IGCCCG (data not shown).
The overall survival of responsive and refractory patients to chemotherapy in the cases evaluated for MSI or BRAF mutation are demonstrated in Fig. 1A and B, respectively. Refractory cases had a poorer overall survival rate compared to responsive cases.
We obtained results of MSI status for 88.7% (133/150) of patients. 126 had a microsatellite stable (MSS) genotype, 7 had MSI-L and none had MSI-H. In a previous study (Campanella et al., 2014) , our group reported that in order to accurately determine MSI-L, the MSI markers of tumor tissue should be compared with the germ-line tissue of the patient. Therefore, for the seven cases with MSI-L, we isolated adjacent normal tissue and identified the presence of an identical MSI marker profile, thereby indicating a MSS phenotype.
The mutation analysis of BRAF V600E was successful in 88% (132/150) of TGTC cases. None were determined to have a BRAF V600E mutation.
All germ cell tumor cell lines were observed to have MSS and wild type BRAF.
DISCUSSION
In our study, we demonstrated an absence of MSI in all TGCT analyzed even in the refractory cases and cell lines. These results are in accordance with several studies, which also did not observe such alterations in TGCT (Lothe et al., 1995; Faulkner & Friedlander, 2000; Olasz et al., 2005; Vladusic et al., 2014) (Table 2 ). In contrast, another study reported the presence of MSI at a significant frequency (33%) and as a potential biomarker of refractory TGCT and poor clinical outcome (Mayer et al., 2011) . Several factors may explain this discrepancy, including differences in methodology, tumor subtype, and ethnically distinct populations. Indeed, the data are still controversial, with MSI frequencies varying from 0 to 33%, and assessing a limited number of cases (Table 2) .
Distinct methodologies have been used in the assessment of MSI in TGCT (Table 2) , including the use of specific microsatellite markers from mononucleotides to tetranucleotides, each of which could lead to different results, as reported for EMAST, an MSI form associated with tetranucleotide repeats (Devaraj et al., 2010; Carethers et al., 2015) . Herein, we used a validated methodology that comprised five quasimonomorphic mononucleotide repeat markers to identify MSI (NR-27, NR-21, NR-24, (Boland et al., 1998) , when an international consensus updated the recommendation and recommended that dinucleotide repeats be substituted for mononucleotide repeats because of improved sensitivity (Buhard et al., 2004) . We utilized this new recommended methodology for this study -a methodology that has been recently validated by our group in the Brazilian population (Campanella et al., 2014) . Other potential causes of differing results may be associated with tumor aggressiveness. Mayer et al. (2002) assessed 111 TGCT cases and 11 of these were refractory to treatment. The authors found a higher rate of MSI in the refractory cases compared to treatment-responsive cases (45 vs. 6%, p = 0.001). It is noteworthy that among refractory cases, the MSI group achieved better median progression free-survival (26 months vs. 6 months, p = 0.05). Although, it is not clear how TGCT was treated in both groups. One hundred unselected cases from study by Mayer et al. were used later as a control cohort in the study by Honecker et al. (2009) (Table 2) . Velasco et al. (2008) assessed the MMR enzyme expression and MSI in 162 TGCT patients, with a majority having seminomas. The authors found a negative correlation between MSI and survival. However, the rate of advanced and high-risk disease was unknown, which may lead to a misinterpretation of the results.
(A) (B) Figure 1 Overall survival of refractory and responsive testicular germ cell tumors cases. (A) microsatellite instability sample; (B) BRAF mutation sample. Another biomarker analyzed in the present study was the BRAF V600E mutation. Herein, we did not identify any case or cell line harboring a BRAF mutation, in accordance with the majority of the studies that addressed this issue after McIntyre et al. (2005) (Table 3) . Nevertheless, some authors have reported BRAF mutations in TGCT, with a frequency up to 28% (Table 3) . Interestingly, Honecker et al. (2009) found that resistant tumors had a higher incidence of BRAF V600E mutations compared with unselected tumors (26 vs. 1%, p = 0.0001) and, for the first time, a correlation between BRAF V600E and cisplatin resistance was reported. Nevertheless, Piulats et al. also assessed BRAF mutation status in 75 men with germ cell tumors; 84% of cases were non-SE and one-third of all cases were refractory to cisplatin. None of these cases exhibited a BRAF V600E mutation (Piulats et al., 2010) . More recently, Satpute et al. (2013) analyzed 59 germ-cell tumors, among these more than half were treatmentrefractory, and no BRAF mutations were identified. Additionally, Feldman et al. (2014) found no BRAF mutations in 46 GCT refractory cases, the largest number of refractory cases already reported. Interestingly, the TCAM2 seminoma cell line was initially reported to exhibit a BRAF mutation (de Jong et al., 2008) . However, other studies did not corroborate these findings even in other germ cell tumor cell lines (Goddard et al., 2010; Feldman et al., 2014) .
Our study is a retrospective analysis and therefore has an inherent selection bias. However, our data are consistent with findings from other studies that show MSI and BRAF mutations are not present in TGCT. This series of 150 cases is very heterogeneous and representative of several types of germ cell tumor histologies, clinical staging, and response rates to chemotherapy. The predominance of advanced disease and non-SE histologies in our series differs from the classical literature, where seminomas and stage I disease are the most common (Ries et al., 2007) . Our hospital is a reference center for TGCT, and affiliated with the Brazilian Childhood Germ Cell Tumor Study Group, a consortium developed to standardize the diagnostic assessment and multidisciplinary treatment of TGCT patients in Brazil (Lopes et al., 2009) . For this reason, our series might be biased by more advanced cases. However, the several risk groups were well represented in the study.
In conclusion, contrasting to other solid tumors, microsatellite instability and BRAF V600E mutation are not present in testicular germ cell tumors, even in treatmentrefractory cases. It is necessary to target other pathways and explore other aspects of genetics and epigenetics in TGCT to better understand its biology and identify new theranostic biomarkers. 
